APA (7th ed.) Citation

Höper, M., Al-Hiti, H., Benza, R. L., Chang, S., Corris, P. A., Gibbs, J. S. R., . . . Simonneau, G. (2021). Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): A multicentre, open-label, randomised controlled trial. The lancet. Respiratory medicine, 9(6), . https://doi.org/10.1016/S2213-2600(20)30532-4

Chicago Style (17th ed.) Citation

Höper, Marius, et al. "Switching to Riociguat Versus Maintenance Therapy with Phosphodiesterase-5 Inhibitors in Patients with Pulmonary Arterial Hypertension (REPLACE): A Multicentre, Open-label, Randomised Controlled Trial." The Lancet. Respiratory Medicine 9, no. 6 (2021). https://doi.org/10.1016/S2213-2600(20)30532-4.

MLA (9th ed.) Citation

Höper, Marius, et al. "Switching to Riociguat Versus Maintenance Therapy with Phosphodiesterase-5 Inhibitors in Patients with Pulmonary Arterial Hypertension (REPLACE): A Multicentre, Open-label, Randomised Controlled Trial." The Lancet. Respiratory Medicine, vol. 9, no. 6, 2021, https://doi.org/10.1016/S2213-2600(20)30532-4.